EPISODE · Oct 23, 2024 · 51 MIN
Cell Therapies that Can Do a Solid for People with Cancer
from The Bio Report · host Levine Media Group
In August, the U.S. Food and Drug Administration approved Adaptimmune’s Tecelra, the first engineered cell therapy to treat a solid tumor. The T cell receptor gene therapy is approved to treat synovial sarcoma, a rare soft tissue cancer that most often affects young adults. We spoke to Adrian Rawcliffe, CEO of Adaptimmune, about the approval, how TCR therapies differ from CAR T therapies, and what other cancers might benefit from such an approach.
What this episode covers
Adrian Rawcliffe, CEO of Adaptimmune, discuses the approval the first engineered cell therapy to treat a solid tumor, how its T cell receptor gene therapies differ from CAR T therapies, and what other cancers might benefit from such an approach.
NOW PLAYING
Cell Therapies that Can Do a Solid for People with Cancer
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m